文献速递免疫规划卫生政策与健康促进

马来西亚BNT162b2、CoronaVac和ChAdOx1疫苗接种后严重不良事件风险:自我对照病例系列研究

Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
PubMed 文献 · Vaccine · 2022-06-03

该研究在马来西亚利用2021年2月1日至9月30日的住院数据与新冠免疫登记链接,采用自我对照病例系列设计,评估接种BNT162b2、CoronaVac和ChAdOx1疫苗后21天内预定诊断的住院风险。结果显示BNT162b2接种者静脉血栓栓塞、心律失常和惊厥/癫痫风险小幅升高,ChAdOx1接种者血小板减少症和静脉血栓栓塞风险升高,CoronaVac除心律失常外无关联,总体安全性可接受。

要点

  • BNT162b2接种后21天内静脉血栓栓塞IRR 1.24、心律失常IRR 1.16、惊厥/癫痫IRR 1.26。
  • ChAdOx1接种后血小板减少症IRR 2.67、静脉血栓栓塞IRR 2.22。
  • CoronaVac除心律失常IRR 1.15外,其他事件无关联。

核心结论

  • 本研究显示BNT162b2、CoronaVac和ChAdOx1新冠疫苗在接种者中具有可接受的安全性特征。
  • 该信息可与有效性数据一起用于疫苗接种项目的风险-获益分析。
  • 需要更多数据的进一步监测以评估新冠疫苗接种后的短期和长期特别关注不良事件。

研究设计与样本

  • 采用自我对照病例系列研究设计。
  • 研究对象为2021年2月1日至2021年9月30日期间马来西亚接种新冠疫苗并诊断为血小板减少症、静脉血栓栓塞、心肌梗死、心肌炎/心包炎、心律失常、卒中、贝尔面瘫和惊厥/癫痫的住院个体。
  • 住院数据与全国新冠免疫登记链接,使用条件泊松回归计算发病率比(IRR)和95%置信区间(CI),并校正日历时期。

主要发现

  • 接种BNT162b2、CoronaVac和ChAdOx1疫苗任一剂次后21天内,心肌炎/心包炎、贝尔面瘫、卒中和心肌梗死风险均未增加。
  • BNT162b2接种者中观察到静脉血栓栓塞风险小幅升高(IRR 1.24;95% CI 1.02, 1.49)、心律失常风险升高(IRR 1.16;95% CI 1.07, 1.26)和惊厥/癫痫风险升高(IRR 1.26;95% CI 1.07, 1.48)。
  • CoronaVac疫苗除心律失常(IRR 1.15;95% CI 1.01, 1.30)外,与其他所有事件均无关联。
  • ChAdOx1疫苗与血小板减少症风险升高(IRR 2.67;95% CI 1.21, 5.89)和静脉血栓栓塞风险升高(IRR 2.22;95% CI 1.17, 4.21)相关。

关键数值与推荐

  • 风险期为接种后21天,对照期为接种后其他时间。
  • BNT162b2:静脉血栓栓塞IRR 1.24(95% CI 1.02, 1.49);心律失常IRR 1.16(95% CI 1.07, 1.26);惊厥/癫痫IRR 1.26(95% CI 1.07, 1.48)。
  • CoronaVac:心律失常IRR 1.15(95% CI 1.01, 1.30)。
  • ChAdOx1:血小板减少症IRR 2.67(95% CI 1.21, 5.89);静脉血栓栓塞IRR 2.22(95% CI 1.17, 4.21)。

临床怎么用

  • 本研究结果可与有效性数据结合用于新冠疫苗接种项目的风险-获益分析。
  • 原文未据此给出推荐。

局限性

  • 需要更多数据的进一步监测以评估新冠疫苗接种后的短期和长期特别关注不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid deployment of COVID-19 vaccines is challenging for safety surveillance, especially on adverse events of special interest (AESIs) that were not identified during the pre-licensure studies. This study evaluated the risk of hospitalisations for predefined diagnoses among the vaccinated population in Malaysia. METHODS: Hospital admissions for selected diagnoses between 1 February 2021 and 30 September 2021 were linked to the national COVID-19 immunisation register. We conducted self-controlled case-series study by identifying individuals who received COVID-19 vaccine and diagnosis of thrombocytopenia, venous thromboembolism, myocardial infarction, myocarditis/pericarditis, arrhythmia, stroke, Bell's Palsy, and convulsion/seizure. The incidence of events was assessed in risk period of 21 days postvaccination relative to the control period. We used conditional Poisson regression to calculate the incidence rate ratio (IRR) and 95% confidence interval (CI) with adjustment for calendar period. RESULTS: There was no increase in the risk for myocarditis/pericarditis, Bell's Palsy, stroke, and myocardial infarction in the 21 days following either dose of BNT162b2, CoronaVac, and ChAdOx1 vaccines. A small increased risk of venous thromboembolism (IRR 1.24; 95% CI 1.02, 1.49), arrhythmia (IRR 1.16, 95% CI 1.07, 1.26), and convulsion/seizure (IRR 1.26; 95% CI 1.07, 1.48) was observed among BNT162b2 recipients. No association between CoronaVac vaccine was found with all events except arrhythmia (IRR 1.15; 95% CI 1.01, 1.30). ChAdOx1 vaccine was associated with an increased risk of thrombocytopenia (IRR 2.67; 95% CI 1.21, 5.89) and venous thromboembolism (IRR 2.22; 95% CI 1.17, 4.21). CONCLUSION: This study shows acceptable safety profiles of COVID-19 vaccines among recipients of BNT162b2, CoronaVac, and ChAdOx1 vaccines. This information can be used together with effectiveness data for risk-benefit analysis of the vaccination program. Further surveillance with more data is required to assess AESIs following COVID-19 vaccination in short- and long-term.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ab Rahman N, Lim MT, Lee FY, et al. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study. Vaccine. 2022. PMID: 35667917. doi:10.1016/j.vaccine.2022.05.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。